AbbVie
American pharmaceutical company
Follow AbbVie on Notably News to receive short updates to your email — rarely!
| December 2024 | AbbVie acquired Nimble Therapeutics, a Roche spinout developing oral peptide treatments in autoimmune areas, for $200 million. |
| October 2024 | AbbVie acquired Aliada Therapeutics for $1.4 billion to expand its neuroscience pipeline. |
| June 1 2024 | Robert Michael replaced Richard Gonzalez as CEO of AbbVie, with Gonzalez becoming executive chairman. |
| March 2024 | AbbVie announced the acquisition of Landos Biopharma for over $200 million. |
| 2023 | Humira began facing competition from Amgen's biosimilar, potentially impacting its market dominance after years of being the company's primary revenue generator. |
| December 2023 | AbbVie announced the acquisition of neuroscience drugmaker Cerevel Therapeutics for $8.7 billion to expand its drug pipeline, completed in August 2024. |
| November 2023 | AbbVie announced the acquisition of ImmunoGen for $10.1 billion to expedite its entry into the ovarian cancer treatment market, with the deal finalized in February 2024. |
| 2022 | Imbruvica was priced at $181,529 annually, with patients taking four pills daily facing a cost of $242,039. |
| July 2022 | AbbVie agreed to pay up to $2.37 billion to settle U.S. lawsuits against its Allergan unit over the marketing of opioid painkillers. The company denied any wrongdoing, and its stock fell 6 percent following an earnings report that included a $2.2 billion charge related to the opioid settlement. |
| March 2022 | AbbVie acquired Syndesi Therapeutics for up to $1 billion, including its portfolio of novel modulators of the synaptic vesicle protein 2A and lead compound SDI-118. |
| June 2021 | AbbVie acquired TeneoOne and its lead compound TNB-383B, a BCMA-targeting immunotherapeutic for relapsed or refractory multiple myeloma. |
| June 2021 | The United States Senate Finance Committee, led by Chair Ron Wyden, initiated an investigation into AbbVie's potential tax avoidance strategies, focusing on the company's stock buybacks and international profit shifting following the 2017 Tax Cuts and Jobs Act. |
| 2020 | AbbVie reported a pretax loss of $4.5 billion in the United States, contrasted with an overseas pretax profit of $7.9 billion, which prompted scrutiny from Senator Ron Wyden regarding potential tax avoidance practices. |
| 2020 | AbbVie's global sales of ibrutinib increased to $5 billion. |
| 2020 | AbbVie agreed to pay $24 million to resolve allegations of kickback schemes promoting its rheumatoid arthritis drug Humira using 'nurse ambassadors'. |
| December 31 2020 | AbbVie reported total CO2e emissions (Direct + Indirect) of 508 kilotonnes, representing a 10.1% year-over-year reduction from the previous year. |
| March 2020 | AbbVie announced plans to evaluate Kaletra/Aluvia HIV medicine as a potential COVID-19 treatment, entering partnerships with health authorities to investigate the drug's efficacy. A non-blinded, randomized trial ultimately found the drug not useful for treating severe COVID-19. |
| March 2020 | During the COVID-19 pandemic, AbbVie responded to the Israeli government's request by voluntarily ceasing enforcement of patents for Kaletra (lopinavir/ritonavir), a HIV/AIDS medication potentially useful in COVID-19 treatment. |
| 2019 | A UK court dismissed AbbVie's legal case against the NHS, concluding against the company's claims of procurement impropriety. |
| July 2019 | AbbVie announced the acquisition of Mavupharma to boost its cancer drug pipeline. |
| June 25 2019 | AbbVie announced its plan to acquire Allergan plc for about $63 billion, with the company remaining legally domiciled in the U.S. for tax purposes. |
| 2018 | AbbVie agreed to pay $25 million to resolve allegations of kickback schemes related to its cholesterol drug Tricor. |
| 2018 | AbbVie initiated litigation against NHS England in the Technology and Construction Court, claiming the agency breached procurement rules and unfairly treated the company during a major hepatitis C treatment procurement process. |
| 2016 | AbbVie estimated global sales of ibrutinib at $1 billion. |
| April 2016 | AbbVie announced co-commercialization of Argenx's preclinical immunotherapy ARGX-115, a first-in-class treatment targeting GARP membrane protein to enhance immunosuppressive effects of T cells. |
| April 2016 | AbbVie partnered with the University of Chicago to investigate oncology areas including breast, lung, prostate, colorectal, and hematological cancers. |
| April 28 2016 | AbbVie announced the acquisition of Stemcentrx for up to $9.8 billion. |
| February 10 2016 | AbbVie and Synlogic announced a multi-year R&D collaboration, with AbbVie obtaining worldwide rights to Synlogic's probiotic-based technology for treating inflammatory bowel diseases, focusing on Crohn's disease and ulcerative colitis. |
| 2015 | AbbVie established its baseline year for carbon emissions reduction goals, targeting a 25% reduction in total CO2e emissions by 2025. |
| May 26 2015 | AbbVie completed the acquisition of Pharmacyclics, retaining its name and operating it as a subsidiary from its Sunnyvale, California headquarters. |
| March 4 2015 | AbbVie announced an agreement to acquire Pharmacyclics for $261.25 per share, with a total acquisition value of approximately $21 billion. |
| October 2014 | AbbVie terminated its efforts to acquire Shire, paying a $1.6 billion breakup fee due to changes in US tax code. |
| September 3 2014 | AbbVie initiated an R&D collaboration with Calico (an Alphabet Inc. subsidiary) to discover and develop new therapies for aging-related diseases including neurodegeneration and cancer. |
| September 3 2014 | AbbVie entered into a global collaboration with Infinity Pharmaceuticals to develop and commercialize duvelisib, a cancer treatment PI3K inhibitor. |
| January 2014 | AbbVie acquired ImmuVen, expanding its pharmaceutical portfolio. |
| 2013 | AbbVie launched Imbruvica, a drug used to treat mantle cell lymphoma and other cancers, which would later see an 82% price increase. |
| January 2 2013 | AbbVie was officially listed on the New York Stock Exchange under the ticker symbol ABBV. |
| January 1 2013 | The separation from Abbott Laboratories was fully completed, establishing AbbVie as an independent company. |
| April 10 2012 | AbbVie was formally formed as a spin-off company from Abbott Laboratories. |
| October 19 2011 | Abbott Laboratories announced its plan to separate into two publicly traded companies, with a spin-off of its research-based pharmaceutical manufacturer division. |
This contents of the box above is based on material from the Wikipedia article AbbVie, which is released under the Creative Commons Attribution-ShareAlike 4.0 International License.